Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (November 2021)

29 slides from Zynerba Pharmaceuticals's investor presentation, Nov 15, 2021

  1. Slide 1: Corporate Overview November 2021

    Corporate Overview November 2021

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S

  3. Slide 3: A Rare/Near-Rare Neuropsychiatric Company

    Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline targeting high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel Ʀ (Cannabidiol Gel) • Focused on completing development of Zygel in Fragile X syndrome (FXS)

  4. Slide 4: Deep Clinical Pipeline & Near-term Milestones

    Deep Clinical Pipeline & Near - term Milestones 4 Zygel Cannabidiol Gel *Orphan Drug and Fast Track designation **Orphan Drug designation Expected Milestones Topline results expected 2H 2023 Company guidance on path forward by end of 2021 Screening of patients has resumed; timing for top line result

  5. Slide 5: Zygel (ZYN002) Cannabidiol Gel

    Neuropsych Indications Differentiated Formulation delivers Cannabidiol through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol Gel 5 Unique Mechanism of Action First & only patent - protected (2038), permeation - enhanced, pharmaceutically - produced cannabidiol gel Transder

  6. Slide 6: Fragile X Syndrome (FXS)

    6 • Rare genetic developmental disability • Leading known cause of both inherited intellectual disability and ASD • No approved drugs indicated for FXS • Symptoms linked to deficiencies in the endocannabinoid system (ECS) • Mutation impacts FMR1 gene and causes ECS dysregulation, causing core cognit

  7. Slide 7: CONNECT-FX Trial Design

    CONNECT - FX Trial Design 7 C linical study O f Ca NN abidiol in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel (n=110; 72 *) 250 mg daily 500 mg daily (weight - based dose) Placebo (n=102; 65 *) Mirrored Zygel administration 14 weeks Three through 17 years of age Open label ext

  8. Slide 8: CONNECT-FX Endpoints and Data Collected

    CONNECT - FX 8 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/Lethargic subscale score •

  9. Slide 9: CONNECT-FX Results: Complete FMR1 Methylation

    9 9 CONNECT - FX Results: Complete FMR1 Methylation Consistent Improvements Observed with Zygel vs. Placebo Caregiver reported behavioral change Clinician reported improvements in behavior Clinically meaningful improvements in behavior Primary endpoint Caregiver Global Impression of Change Any Impro

  10. Slide 10: CONNECT-FX: Safety

    CONNECT - FX: Safety 10 • Zygel was very well tolerated • No serious or severe adverse events reported during the trial • All treatment - emergent adverse events (TEAEs; any event, whether unrelated or related to study drug) were mild or moderate • Most common treatment - related TEAE: application s

  11. Slide 11: RECONNECT Trial Design

    Trial Design 11 R andomiz e d, Double - Blind, Pla c ebo - C on trolled, Multiple - Ce n ter, Effica c y and Safe t y Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome Zygel ( n~100 ; 80*) 250 mg daily ( ≤ 30kg) 500 mg daily (> 30kg ) 750 mg daily

  12. Slide 12: RECONNECT Endpoints

    Primary endpoint • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of the FMR1 gene Secondary endpoints • Change from baseline to end of treatment in: • ABC - C FXS Irritability subscale in patients who have complete

  13. Slide 13: Key study design elements

    Key study design elements • 18 week trial design will allow us to evaluate improvement in behavioral symptoms over time • Added a third dosing group of 750 mg for individuals >50 kg to maintain appropriate dosing levels for patients • Made trial more patient and family friendly than CONNECT – FX tri

  14. Slide 14: Autism Spectrum Disorder

    14 • Near - rare disorder • Symptoms include irritability; anxiety, restricted, repetitive patterns of behavior; impairments in social communication; deficits in verbal and non - verbal communication; deficits in developing, understanding and maintaining relationships • Most diagnosed after age 4; c

  15. Slide 15: BRIGHT Phase 2 Trial in ASD

    BRIGHT Phase 2 Trial in ASD 15 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder 37 pts with moderate - to - severe ASD enrolled Three through 17 years of age Screening Zygel 14 Weeks Weight b

  16. Slide 16: Results of BRIGHT Phase 2 Trial

    16 16 Results of BRIGHT Phase 2 Trial Autism symptom frequency and impact Parental stress Qualitative caregiver assessments Severity of anxiety Primary efficacy objective ABC - C subscales % improvement Irritability: 39.1% ( p <0.0001*) Inappropriate Speech: 42.5% ( p =0.0002*) Stereotypy: 39.1% ( p

  17. Slide 17: BRIGHT Statistically Significant Improvements Through Week 38

    17 *Lower values reflect improvement in each ABC - C subscale. Mean Scores and Percent Improvement Through Week 38* 31.6 7.4 12.7 27.6 36.1 14.3 4.0 6.2 14.0 19.5 13.3 3.8 4.8 10.9 16.8 0 10 20 30 40 Irritability Inappropriate Speech Stereotypy Social Withdrawal Hyperactivity Baseline Week 14 Week 3

  18. Slide 18: Well Tolerated Safety Profile in BRIGHT Trial in ASD

    • Well tolerated and consistent with previously released data at week 14 and week 38, compared to baseline • Approximately half the patients experienced a treatment - emergent adverse event (TEAE; any event, whether unrelated or related to study drug): 49% through week 14 and 54% at week 38 • Most w

  19. Slide 19: Next Steps in ASD Program

    Next Steps in ASD Program 19 • In 1H 2021, Zynerba discussed data supporting the potential efficacy of Zygel in ASD, including the results of the Phase 2 BRIGHT trial, with the FDA to determine the regulatory path forward • Positive guidance from FDA included agreement on utilizing the irritability

  20. Slide 20: 22q11.2 Deletion Syndrome

    20 • Rare disorder; most common contiguous gene deletion syndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities common • 22q associated with increa

  21. Slide 21: INSPIRE Phase 2 Trial in 22q

    INSPIRE Phase 2 Trial in 22q 21 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily Efficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community (ABC - C) • Anxiety, Depression and Mood Scale (

  22. Slide 22: Developmental and Epileptic Encephalopathies

    22 • Group of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral palsy, chronic respiratory infection

  23. Slide 23: BELIEVE Phase 2 Trial in DEE

    BELIEVE Phase 2 Trial in DEE 23 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titr

  24. Slide 24: Results of BELIEVE Phase 2 Trial

    24 24 Results of BELIEVE Phase 2 Trial Clinically Meaningful Improvements in FIAS / TCS and QoL vs. Baseline ≥35% and ≥50% responders Reductions in seizures in patients with ASD Improved Sleep Qualitative assessments Primary efficacy objective Median % Reductions in Seizures Month 3 (n=33): 44% Mont

  25. Slide 25: BELIEVE Safety

    25 • Tolerability profile consistent with the safety database for Zygel • Most treatment - emergent adverse events (TEAEs) (any event, whether unrelated or related to study drug) were mild or moderate • Two SAEs deemed possibly drug - related (LRTI and status epilepticus) • No drug - related clinica

  26. Slide 26: BELIEVE Results Published in JAMA Network Open

    BELIEVE Phase 2 Trial in DEE 26 Results Published in JAMA Network Open , September 3, 2021 • The authors concluded that Zygel was safe, well tolerated, and was associated with reductions in focal impaired awareness seizures (FIAS) and tonic - clonic seizure (TCS) frequency and disease burden • The a

  27. Slide 27: Financial Strength

    Financial Strength 27 • Clean balance sheet • No debt, 41.2M shares outstanding (as of November 11, 2021) • Cash and cash equivalent position of $ 75.6M as of September 30, 2021 • Cash runway expected to be sufficient to fund operations and capital requirements well into the first half of 2024

  28. Slide 28: Deep Clinical Pipeline & Near-term Milestones

    Deep Clinical Pipeline & Near - term Milestones 28 Zygel Cannabidiol Gel *Orphan Drug and Fast Track designation **Orphan Drug designation Expected Milestones Topline results expected 2H 2023 Company guidance on path forward by end of 2021 Screening of patients has resumed; timing for top line resul

  29. Slide 29: Corporate Overview November 2021

    Corporate Overview November 2021

Zynerba Pharmaceuticals — Investor Presentation (November 2021) on 6ix